Advertisement
Screener

REPLIGEN CORP (RGEN) Investing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

REPLIGEN CORP Investing Cash Flow

REPLIGEN CORP (RGEN) reported Investing Cash Flow of -$6.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-29

  • REPLIGEN CORP net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$2.09M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$3.99M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$208.74M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$7.78M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for fiscal 2025 was -$298.47M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for fiscal 2024 was -$86.38M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for fiscal 2023 was -$123.28M.
  • REPLIGEN CORP net cash provided by (used in) investing activities for fiscal 2022 was -$233.24M.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 12 month
2026-06-30-$2.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
-$6.08M
10-Q · filed 2026-07-29
-$214.82M
derived: sum of 3 quarters · filed 2026-07-29
-$222.60M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31-$3.99M
10-Q · filed 2026-05-06
-$212.73M
derived: sum of 2 quarters · filed 2026-05-06
-$220.51M
derived: sum of 3 quarters · filed 2026-05-06
-$228.35M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31-$208.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$216.53M
derived: sum of 2 quarters · filed 2026-02-26
-$224.37M
derived: sum of 3 quarters · filed 2026-07-29
-$298.47M
10-K · filed 2026-02-26
2025-09-30-$7.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$15.62M
derived: sum of 2 quarters · filed 2026-07-29
-$89.73M
10-Q · filed 2025-11-04
-$154.49M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30-$7.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
-$81.95M
10-Q · filed 2026-07-29
-$146.71M
derived: sum of 3 quarters · filed 2026-07-29
-$152.57M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31-$74.11M
10-Q · filed 2026-05-06
-$138.87M
derived: sum of 2 quarters · filed 2026-05-06
-$144.73M
derived: sum of 3 quarters · filed 2026-05-06
-$152.13M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31-$64.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$70.62M
derived: sum of 2 quarters · filed 2026-02-26
-$78.02M
derived: sum of 3 quarters · filed 2026-02-26
-$86.38M
10-K · filed 2026-02-26
2024-09-30-$5.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
-$13.26M
derived: sum of 2 quarters · filed 2025-11-04
-$21.62M
10-Q · filed 2025-11-04
-$191.53M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30-$7.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$15.76M
10-Q · filed 2025-08-07
-$185.67M
derived: sum of 3 quarters · filed 2026-02-26
-$194.44M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$8.36M
10-Q · filed 2025-04-29
-$178.27M
derived: sum of 2 quarters · filed 2026-02-26
-$187.04M
derived: sum of 3 quarters · filed 2026-02-26
-$122.20M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31-$169.91M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26
-$178.68M
derived: sum of 2 quarters · filed 2026-02-26
-$113.84M
derived: sum of 3 quarters · filed 2026-02-26
-$123.28M
10-K · filed 2026-02-26
2023-09-30-$8.77M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
$56.06M
derived: sum of 2 quarters · filed 2024-11-18
$46.63M
10-Q/A · filed 2024-11-18
-$74.68M
derived: sum of 4 quarters · filed 2025-03-14
2023-06-30$64.83M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
$55.40M
10-Q/A · filed 2024-11-18
-$65.91M
derived: sum of 3 quarters · filed 2025-03-14
-$123.40M
derived: sum of 4 quarters · filed 2025-03-14
2023-03-31-$9.43M
10-Q/A · filed 2024-11-18
-$130.74M
derived: sum of 2 quarters · filed 2025-03-14
-$188.24M
derived: sum of 3 quarters · filed 2025-03-14
-$214.46M
derived: sum of 4 quarters · filed 2025-03-14
2022-12-31-$121.31M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14
-$178.80M
derived: sum of 2 quarters · filed 2025-03-14
-$205.02M
derived: sum of 3 quarters · filed 2025-03-14
-$233.24M
10-K · filed 2025-03-14
2022-09-30-$57.49M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
-$83.71M
derived: sum of 2 quarters · filed 2024-11-18
-$111.93M
10-Q/A · filed 2024-11-18
-$174.20M
derived: sum of 4 quarters · filed 2024-11-18
2022-06-30-$26.22M
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
-$54.43M
10-Q/A · filed 2024-11-18
-$116.71M
derived: sum of 3 quarters · filed 2024-11-18
-$249.41M
derived: sum of 4 quarters · filed 2024-11-18
2022-03-31-$28.21M
10-Q/A · filed 2024-11-18
-$90.49M
derived: sum of 2 quarters · filed 2024-11-18
-$223.19M
derived: sum of 3 quarters · filed 2024-11-18
-$240.39M
derived: sum of 4 quarters · filed 2024-11-18
2021-12-31-$62.28M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18
-$194.97M
derived: sum of 2 quarters · filed 2024-11-18
-$212.17M
derived: sum of 3 quarters · filed 2024-11-18
-$221.17M
10-K/A · filed 2024-11-18
2021-09-30-$132.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
-$149.90M
derived: sum of 2 quarters · filed 2022-11-01
-$158.89M
10-Q · filed 2022-11-01
-$317.18M
derived: sum of 4 quarters · filed 2023-02-22
2021-06-30-$17.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02
-$26.20M
10-Q · filed 2022-08-02
-$184.49M
derived: sum of 3 quarters · filed 2023-02-22
-$218.07M
derived: sum of 4 quarters · filed 2023-02-22
2021-03-31-$9.00M
10-Q · filed 2022-04-27
-$167.28M
derived: sum of 2 quarters · filed 2023-02-22
-$200.87M
derived: sum of 3 quarters · filed 2023-02-22
-$205.34M
derived: sum of 4 quarters · filed 2023-02-22
2020-12-31-$158.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
-$191.87M
derived: sum of 2 quarters · filed 2023-02-22
-$196.35M
derived: sum of 3 quarters · filed 2023-02-22
-$201.38M
10-K · filed 2023-02-22
2020-09-30-$33.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
-$38.06M
derived: sum of 2 quarters · filed 2021-10-28
-$43.10M
10-Q · filed 2021-10-28
-$50.21M
derived: sum of 4 quarters · filed 2022-02-17
2020-06-30-$4.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27
-$9.52M
10-Q · filed 2021-07-27
-$16.63M
derived: sum of 3 quarters · filed 2022-02-17
-$23.52M
derived: sum of 4 quarters · filed 2022-02-17
2020-03-31-$5.04M
10-Q · filed 2021-05-04
-$12.15M
derived: sum of 2 quarters · filed 2022-02-17
-$19.04M
derived: sum of 3 quarters · filed 2022-02-17
-$206.52M
derived: sum of 4 quarters · filed 2022-02-17
2019-12-31-$7.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17
-$14.00M
derived: sum of 2 quarters · filed 2022-02-17
-$201.48M
derived: sum of 3 quarters · filed 2022-02-17
-$205.31M
10-K · filed 2022-02-17
2019-09-30-$6.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$194.37M
derived: sum of 2 quarters · filed 2020-11-05
-$198.20M
10-Q · filed 2020-11-05
-$203.65M
derived: sum of 4 quarters · filed 2021-02-24
2019-06-30-$187.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
-$191.31M
10-Q · filed 2020-07-30
-$196.76M
derived: sum of 3 quarters · filed 2021-02-24
-$200.93M
derived: sum of 4 quarters · filed 2021-02-24
2019-03-31-$3.83M
10-Q · filed 2020-05-06
-$9.29M
derived: sum of 2 quarters · filed 2021-02-24
-$13.45M
derived: sum of 3 quarters · filed 2021-02-24
-$16.30M
derived: sum of 4 quarters · filed 2021-02-24
2018-12-31-$5.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
-$9.63M
derived: sum of 2 quarters · filed 2021-02-24
-$12.47M
derived: sum of 3 quarters · filed 2021-02-24
-$14.04M
10-K · filed 2021-02-24
2018-09-30-$4.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
-$7.02M
derived: sum of 2 quarters · filed 2019-10-31
-$8.58M
10-Q · filed 2019-10-31
-$10.20M
derived: sum of 4 quarters · filed 2020-02-26
2018-06-30-$2.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
-$4.41M
10-Q · filed 2019-08-01
-$6.03M
derived: sum of 3 quarters · filed 2020-02-26
-$117.24M
derived: sum of 4 quarters · filed 2020-02-26
2018-03-31-$1.56M
10-Q · filed 2019-05-09
-$3.19M
derived: sum of 2 quarters · filed 2020-02-26
-$114.39M
derived: sum of 3 quarters · filed 2020-02-26
2017-12-31-$1.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26
-$112.83M
derived: sum of 2 quarters · filed 2020-02-26
-$98.70M
10-K · filed 2020-02-26
2017-09-30-$111.21M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
-$97.08M
10-Q · filed 2018-11-01
2017-06-30$14.13M
10-Q · filed 2018-08-02
2016-12-31-$49.19M
10-K · filed 2019-03-01
2013-12-31-$10.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
-$12.10M
derived: sum of 2 quarters · filed 2014-03-14
-$12.86M
derived: sum of 3 quarters · filed 2014-03-14
-$17.91M
10-K · filed 2014-03-14
2013-09-30-$2.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
-$2.83M
derived: sum of 2 quarters · filed 2013-11-08
-$7.88M
10-Q · filed 2013-11-08
-$4.74M
derived: sum of 4 quarters · filed 2014-03-14
2013-06-30-$761.66K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
-$5.81M
10-Q · filed 2013-08-07
-$2.67M
derived: sum of 3 quarters · filed 2014-03-14
-$3.96M
derived: sum of 4 quarters · filed 2014-03-14
2013-03-31-$5.05M
10-Q · filed 2013-05-07
-$1.91M
derived: sum of 2 quarters · filed 2014-03-14
-$3.20M
derived: sum of 3 quarters · filed 2014-03-14
-$1.82M
derived: sum of 4 quarters · filed 2014-03-14
2012-12-31$3.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$1.85M
derived: sum of 2 quarters · filed 2014-03-14
$3.23M
derived: sum of 3 quarters · filed 2014-03-14
$2.84M
10-K · filed 2014-03-14
2012-09-30-$1.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$86.53K
derived: sum of 2 quarters · filed 2013-11-08
-$299.37K
10-Q · filed 2013-11-08
-$4.50M
derived: sum of 4 quarters · filed 2014-03-14
2012-06-30$1.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$992.77K
10-Q · filed 2013-08-07
-$3.21M
derived: sum of 3 quarters · filed 2014-03-14
$8.52K
derived: sum of 4 quarters · filed 2014-03-14
2012-03-31-$385.90K
10-Q · filed 2013-05-07
-$4.59M
derived: sum of 2 quarters · filed 2014-03-14
-$1.37M
derived: sum of 3 quarters · filed 2014-03-14
-$5.40M
derived: sum of 4 quarters · filed 2014-03-14
2011-12-31-$4.20M
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
-$984.25K
derived: sum of 2 quarters · filed 2014-03-14
-$5.01M
10-K · filed 2014-03-14
-$2.03M
derived: sum of 4 quarters · filed 2014-03-14
2011-09-30$3.22M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
-$810.09K
10-Q · filed 2011-11-09
$2.17M
10-Q · filed 2012-11-08
-$4.25M
derived: sum of 4 quarters · filed 2014-03-14
2011-06-30-$4.03M
10-Q · filed 2011-08-05
-$1.04M
10-Q · filed 2012-08-09
-$7.47M
derived: sum of 3 quarters · filed 2014-03-14
-$1.78M
derived: sum of 4 quarters · filed 2014-03-14
2011-03-31$2.98M
10-Q · filed 2012-05-10
-$3.44M
derived: sum of 2 quarters · filed 2014-03-14
$2.24M
derived: sum of 3 quarters · filed 2014-03-14
-$1.50M
10-K · filed 2013-03-15
2010-12-31-$6.43M
derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14
-$739.67K
derived: sum of 2 quarters · filed 2014-03-14
-$4.49M
10-K · filed 2014-03-14
2010-09-30$5.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09
$1.94M
10-Q · filed 2011-11-09
2010-06-30-$3.75M
10-Q · filed 2011-08-05
2010-03-31$9.92M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78